Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 6,832 | 72 | 72 | 1,194 | 20,759 |
| Gross Profit | 6,832 | 72 | 72 | 1,194 | 20,759 |
| Operating Expenses | 23,666 | 46,835 | 70,203 | 82,696 | 75,517 |
| Operating Income | -16,834 | -46,763 | -70,131 | -81,502 | -54,758 |
| Interest Expense | 2,131 | 2,343 | 2,723 | 1,182 | 52 |
| Other Income | 374 | 459 | 752 | 844 | -956 |
| Pre-tax Income | -18,591 | -48,647 | -72,102 | -81,840 | -55,766 |
| Income Tax | 1 | 62 | -197 | -4 | -18 |
| Net Income Continuous | -18,592 | -48,709 | -71,905 | -81,836 | -55,748 |
| Net Income | $-18,592 | $-48,709 | $-71,905 | $-81,836 | $-55,748 |
| EPS Basic Total Ops | -10.80 | -55.90 | -114.70 | -185.90 | -129.65 |
| EPS Basic Continuous Ops | -10.77 | -55.87 | -114.68 | -185.91 | -130.18 |
| EPS Diluted Total Ops | -10.80 | -55.90 | -114.70 | -185.90 | -129.65 |
| EPS Diluted Continuous Ops | -10.77 | -55.87 | -114.68 | -185.91 | -130.18 |
| EPS Diluted Before Non-Recurring Items | -10.80 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-15,903 | $-44,353 | $-67,258 | $-78,560 | $-51,695 |